Designed to help Canadians find investment solutions to the two big problems they’re facing: low interest rates and volatile stock markets, the Income Investor was chosen by The Globe and Mail as one of the top five investment newsletters in Canada. If you need income from investments with minimal risk, the Income Investor covers all types of income securities including income trusts, preferred shares, high-yielding common stocks, bonds, mutual funds, exchange-traded funds, and GICs. Any security that generates cash flow is fair game for our experts.

Edited and published by Gordon Pape. Editor: Mike Keerma.

With Gavin Graham, Shawn Allen, Adam Mayers, & Paul Bamford.

Recent Issues

tii2505 (March 13, 2025)

Three tariff-fighting stocks… Gordon Pape updates Freehold Royalties… Gavin Graham updates retail REITs… Your Questions: Capital Power

tii2504 (February 27, 2025)

Innergex takeover… When will REITs recover?… This month’s Top Pick: CAP REIT… Gavin Graham updates grocery-anchored REITs… RRIF Portfolio inches higher

tii2503 (February 13, 2025)

BCE disappoints again… Quality stocks with 6%+ yields… Top Pick: LyondellBasell Industries… Adam Mayers updates Corby Spirit and Wine… Your Questions: Brookfield Infrastructure

tii2502 (January 30, 2025)

Hedged, unhedged, US dollars – an investor’s guide… The elephant in the room… Richard Croft updates Power Corp., CIBC… This month’s Top Pick: AT&T… A good time for pipeline stocks… Gordon Pape updates iShares 0-5 Years TIPS Bond Index ETF, Emera Inc…. Your Questions: Preferred shares

tii2501 (January 15, 2025)

The Trump defence… Hydro One is a portfolio anchor… A good year for dividends

tii2424 (December 18, 2024)

Top income stocks of 2024… An eventful year for Canadian banks… Gavin Graham updates Scotiabank, National Bank, Definity Financial Group, Guardian Group, Capital Power… Gordon Pape updates Gibson Energy, Keyera, Pembina Pipeline… Correction… Price increase…Your Questions: Adding more fixed income, XSTP return

tii2423 (December 5, 2024)

Disney back on track… Top Pick: The Walt Disney Co…. Adam Mayers’s updates… Gavin Graham updates AltaGas, Boralex… Your Questions: Atlantica sale… Price increase

Newer issues Older issues

Recent Updates

Boardwalk REIT (TSX: BEI.UN)

Boardwalk is the largest apartment REIT in Alberta and Saskatchewan, with 64.3% of its units in Alberta. As Alberta has no rent controls, Boardwalk is able to benefit from increases in rents driven by market forces. The province is the cheapest major urban market for rents and enjoys inward migration from more expensive provinces.


Buy


Watts Water Systems (NYSE: WTS)

Watts Water is a provider of market-leading brands in water solutions, with annual sales of $1.8 billion in 2021. Its divisions provide the highest level of performance in the safeguarding of water systems, driven by code and certification, address energy efficiency needs by offering the most efficient conversion of energy sources into heat and hot water, and deliver drainage and pre-treatment systems that help with water conservation projects.


Buy


UK iShares MSCI ETF (NYSE: EWU)

This ETF invests in the UK’s FTSE100 Index, which consists mostly of large-capitalization U.K.-based companies. Launched in March 1996, it has US$3 billion in assets under management and has a reasonable MER of 0.5%.


Buy


Algonquin Power & Utilities Corp. (TSX, NYSE: AQN)

Algonquin’s transition into a conventional utility is paying off. The company reported first-quarter adjusted earnings of $111.6 million ($0.14 a share), up from $80.1 million ($0.11 a share) in the same period last year. Note that the company reports in US dollars.

“The company recorded a constructive first quarter of 2025 with notable year-over-year improvements in our key financial metrics,” said CEO Rod West, who took over the job in March. “Our results were solid, reflecting the strength of our core regulated utility operations.”


Hold


Johnson & Johnson (NYSE: JNJ)

Johnson & Johnson (JNJ) is one of the largest healthcare companies in the world. It employs over 120,000 people in its two divisions, Pharmaceutical and MedTech. It spun off its consumer healthcare division in 2023, naming it Kenvue. About 64% of its $88.8 billion in 2024 revenues came from its pharmaceutical division, while the remaining 36% was from its MedTech operations.


Buy